Savvy Updates, 4/3/23: Glucose-run Fuel Cell to Power Insulin Release, Inreda Diabetic AP Coming to Market 2024, Biomea Fusion BMF-219 May Preserve Beta Cells, Bigfoot Biomedical Buys Insulin Titration Algorithm, Verapamil Preserves C-Peptide Levels, OOP Cost of Diabetes Medications, PBMs Under Scrutiny, Splenda® Stevia Farm
Scientists use implanted glucose-run fuel cell to power insulin release by Nick Paul Taylor for MedTechDive.com, 29 March 2023. There is a need for better ways to power medical implants. Devices either have a battery that gradually runs down and...
Savvy Update, 3/27/23: Non-Invasive Monitoring: Know Labs & Hagar’s GWave, California’s Brand of Insulin, Steatosis in Adult T1Ds, MDs Leaving Their Jobs, Colorectal Cancers in Adult T1Ds, Off-Label Prescribing
Know Labs establishes scientific advisory board to advance non-invasive glucose monitoring by Sean Whooley for DrugDeliveryBusiness.com, 22 March 2023. Know Labs announced that it established a scientific advisory board to accelerate the development of its glucose...
Savvy on Gut Microbiome and Type 1 Diabetes, 3/24/23
Today’s post focuses on the gut microbiome and how it impacts management of Type 1 Diabetes The incidence of autoimmune type 1 diabetes (T1D) is increasing worldwide and disease onset tends to occur at a younger age. Unfortunately, clinical trials aiming to...
Savvy Updates, 3/20/23: Vertex Cleared for VX-264 Trials, Nemaura Medical & SugarBeat, Insulin Leads to Smaller Pancreas, Insulet Joins S&P500, Insulin Costs & Price Cuts, Sanofi Buys ProventionBio
New Vertex Type 1 Stem Cell Therapy Gets FDA Nod to Enter Clinical Trials by Andrew Briskin for diaTribe.org, 9 March 2023. The FDA announced that a new type 1 diabetes stem cell therapy from Vertex has been cleared to enter clinical trials in the United...
Savvy Updates, 3/6/23: Lilly Insulin Price Cuts, Erythritol & Heart Risk, iCare, Bigfoot Unity, Fully Closed-Loops
Eli Lilly to Cut Price of Insulin by 70%, Cap Insulin Costs at $35 a Month by Susannah Chen and Natalie Sainz for diaTribe.org, 1 March 2023. Eli Lilly announced that it will cut the list prices for its most commonly prescribed insulins by 70%. The drug...
More Diabetes Blogs